Forte Biosciences (FBRX) Net Equity Issued and Repurchased (2016 - 2025)

Forte Biosciences (FBRX) has 9 years of Net Equity Issued and Repurchased data on file, last reported at -$73.2 million in Q3 2025.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to -$73.2 million in Q3 2025; TTM through Dec 2025 was -$73.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.8 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased for Q3 2025 stood at -$73.2 million, down from $8000.0 in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for FBRX reached as high as $25.0 million in Q1 2022 and fell as low as -$73.2 million in Q3 2025.
• Historically, Net Equity Issued and Repurchased has averaged -$1.1 million across 4 years, with a median of $7.7 million in 2022.
• On a YoY basis, Net Equity Issued and Repurchased climbed as much as 221.9% in 2023 and fell as far as 99.98% in 2023.
• Year by year, Net Equity Issued and Repurchased stood at $7.7 million in 2022, then surged by 221.9% to $24.8 million in 2023, then sank by 99.97% to $8000.0 in 2024, then plunged by 915362.5% to -$73.2 million in 2025.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were -$73.2 million in Q3 2025, $8000.0 in Q1 2024, and $24.8 million in Q3 2023.